Navigation Links
UK Must Maintain its Momentum in Stem Cell Expertise
Date:1/19/2009

LONDON, January 19 /PRNewswire/ -- Excalibur, the international investment house specialising in medical sciences, said today the UK must 'maintain its momentum' to deliver pioneering stem cell treatments if it is to remain at the forefront of medical technology.

Professor Sir Christopher Evans, founder and chairman of Excalibur, welcomed the announcement that ReNeuron plc has received approval from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) to commence a first-in-man clinical trial for the treatment of patients who have been left disabled by an ischaemic stroke.

Sir Christopher said: "We founded ReNeuron with Dr John Sinden and have invested in the company every step of the way for the last 10 years. We are proud the company has now reached this important milestone in its development of cell therapy treatment for stroke. There have been many scientific and financial hurdles to overcome during these years but we were determined to see this through.

"It is absolutely essential that we in the UK maintain our momentum in stem cell development and our belief in our ability to deliver these potentially revolutionary treatments. Too often in this country there is a tendency to focus on potentially negative outcomes but today's announcement is extremely important news for victims of stroke. At the end of the day lives - and the future of medicine in this area -- could be transformed by this science."

NOTES TO EDITORS

About Excalibur

Excalibur was launched in April 2008 following the acquisition of MVIL by Merlin Biosciences. Excalibur, which has a team of ten professionals, provides a wide range of investment and advisory services to the medical sciences sector. Its latest fund, Merlin Fund III, has successfully invested in a wide range of healthcare and medical sciences companies including PIramed which was sold for $185m in May 2008. Excalibur intends to replicate this successful investment strategy in the new funds that it is proposing to launch over the next 12 months.

Merlin originally founded ReNeuron in 1998 and has provided funding for the company over the last 10 years through Merlin 's Fund l and ll and has continued to invest in and support the company.

Further information: Ramsay Smith, Media House, +44(0)207-397-8459, Email:ramsay@mediahouse.co.uk, mobile +44(0)7788-414856.


'/>"/>
SOURCE Excalibur
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Dynavaxs HEPLISAV(TM) Hepatitis B Vaccine Maintains Full Immunogenicity at 50 Weeks in Phase 3 Trial
2. Lifesaving Benefits of Low-Dose Aspirin Therapy Maintained With Naproxen Sodium
3. Update From Mipomersen Extended Dosing Study Continues to Show That Mipomersen Is Well Tolerated and Maintains Activity in Patients Treated for Up to 16 Months
4. Abbott Presents Long-Term Data From Extension Study Showing Adult Crohns Patients Treated With HUMIRA(R) (Adalimumab) Maintained Remission
5. Olanzapine Long-Acting Injection (LAI) Shown to Maintain Treatment Benefit in Schizophrenia for up to Six Months
6. Xalieve(TM) Gains Momentum as Calabar AB Launches a Phase II Repeated Dose Study in Dry Mouth Patients
7. K-State Researchers Bringing Expertise to Kansas City Symposium on Disease and National Security
8. Enobia Pharma Appoints Industry Veterans with Commercial and Manufacturing Expertise to Expand Senior Management Team
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 2016 Dublin ... addition of the " Global Markets for Spectroscopy ... This report focuses on the ... review, including its applications in various applications. The report ... includes three main industries: pharmaceutical and biotechnology, food and ...
(Date:6/24/2016)... SAN CLEMENTE, Calif. , June 24, 2016 /PRNewswire/ ... pulmonary function testing company, is now able to perform sophisticated lung ... ndd Medical Technologies , Inc. Patients are ... labs.  Thanks to ndd,s EasyOne PRO ® , ARL patients like ... any needed testing done in the comfort of her own home. ...
(Date:6/24/2016)... Belgium , June 24, 2016 ... the appointment of Dr. Edward Futcher ... Non-Executive Director, effective June 23, 2016.Dr. Futcher was ... Nominations and Governance Committees.  As a non-executive member ... independent expertise and strategic counsel to VolitionRx in ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the American ... Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. ... including advance care planning, healthcare costs and patient and family engagement. , AIR ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe ... from the David Geffen School of Medicine at UCLA. He trained in Internal Medicine ... his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set ... drug or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, ... traumatic event. , Trauma sufferers tend to feel a range of emotions, from depression, ...
(Date:6/24/2016)... ... 24, 2016 , ... Dr. Amanda Cheng, an orthodontist ... has extensive experience with all areas of orthodontics, including robotic Suresmile technology, ... , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can be used ...
(Date:6/24/2016)... NY (PRWEB) , ... June 24, 2016 , ... ... Haute Living, is proud to recognize Dr. Barry M. Weintraub as a prominent ... “the most beautiful women in the world, and the most handsome men, look ...
Breaking Medicine News(10 mins):